Return to Latest Press Releases

 

Akrimax Pharmaceuticals Announces Co-Sponsorship of the CME symposium at this year’s 15th International Thyroid Congress

Symposium will educate attendees on T4/T3 therapy treatment for hypothyroidism

Cranford, NJ (June, 2015) – Akrimax Pharmaceuticals, LLC, a privately held, innovative specialty pharmaceutical company, today announced that it will co-sponsor a CME symposium at this year’s 15th International Thyroid Congress (ITC). The ITC is a convention held every five years, hosted by four thyroid associations known worldwide: American Thyroid Association (ATA), Asia-Oceania Thyroid Association, European Thyroid Association, and Latin American Thyroid Society. The ATA and the University of Colorado School of Medicine are jointly responsible for hosting the 15th ITC Continuing Medical Education. The University of Colorado School of Medicine is officially recognized by the Accreditation Council for Continuing Medical Education to continue to educate medical physicians.

Akrimax and Institut Biochimique SA (IBSA) will jointly sponsor the symposium called “T4/T3 Therapy” on October 19th at 1:50 pm. During the symposium, Dr. Colin M. Dayan, Director of the Institute of Molecular & Experimental Medicine at Cardiff University, will be discussing why patients prefer T4/T3 therapy. Chair of the Division of Endocrinology and Metabolism at Virginia Commonwealth University, Dr. Francesco Celi, will review the mechanism for enhanced weight loss with T3. The risks and benefits of combination therapy will be explained by Dr. Anne R. Cappola, an Associate Professor of Medicine in the Division of Endocrinology, Diabetes, and Metabolism at the Perelman School of Medicine at the University of Pennsylvania.

Dr. Keith Rotenberg, Corporate Vice President and Chief Scientific Officer of Akrimax Pharmaceuticals, stated, “Akrimax is proud to sponsor the 15th International Thyroid Congress and the continuation of medical education. We hope that the 15th ITC will further inform physicians on new medical findings and help them to better manage patient care. We believe that Tirosint® (levothyroxine sodium) capsules provide unique benefits for T4 therapy treatment and are excited to share these important benefits to help millions of patients suffering from hypothyroidism.” Click here to see Tirosint® Full Prescribing Information including Black Box Warning.

Akrimax and IBSA are planning to exhibit at the conference. Akrimax will have an exhibit alongside IBSA, the manufacturers of Tirosint®, which will provide information to educate healthcare professionals attending ITC on the use of Tirosint® for patients with hypothyroidism.

The 15th ITC will take place from October 18th to the 23rd at the Walt Disney World Swan and Dolphin Resort in Lake Buena Vista, Florida.

[PR About Hypothyroidism]
[PR About Tirosint]
[PR Tirosint Safety]
[PR About Akrimax ]
[PR Hypothyroidism References]

Contacts

Business Development: J. Gregory Ford, 908-372-1232, gford@akrimax.com
Marketing: Mackenzie Ford, mford@akrimax.com